CorriXR Therapeutics, InhaTarget Therapeutics, and Merxin Ltd Announce Strategic Collaboration for the Development of Inhaled Lung Cancer Treatment

CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform ...
European Medical Journal

Editor’s Pick: Integrated Multi-omics Approaches in Non-small Cell Lung Cancer for Biomarker and Pathway Discovery

Lung cancer remains the most frequently diagnosed malignancy and the leading cause of cancer tumour-related mortality ...
Cancer Therapy Advisor

Medicaid Expansion Reduces Mortality in Non-Small Cell Lung Cancer

In this study, researchers sought to determine whether Medicaid expansion led to improvements in survival for patients with resectable NSCLC.
European Medical Journal

Navigating a Dynamic Treatment Landscape: Established Therapies and Emerging Modalities for Patients with Lung Cancer

Over the past two decades, thoracic oncology has undergone a profound transformation, moving from limited chemotherapy ...
Le Lézard

CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Metastatic Non-squamous NSCLC

CatalYm today announced that the first patient has been dosed in the randomized Phase 2b GDFATHER?NSCLC?02 (GDF?15 Antibody?MediaTed?Human?Effector?T?Cell Relocation) trial (NCT07246863). The trial ...
Pharmabiz

Bristol Myers Squibb data at ASH 2025 showcase potential of haematology pipeline and build momentum for next generation portfolio

Opdivo (nivolumab), in combination with Yervoy (ipilimumab), is indicated for the treatment of adult and paediatric patients 12 years and older with unresectable or metastatic microsatellite ...
Oncology Nursing News

What Oncology Therapies Were Approved by the FDA in November?

The FDA approved the combination of durvalumab (Imfinzi) plus FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and ...
Santé log

MAIA Biotechnology Announces Open Market Purchases by CEO and Directors

Vlad Vitoc, M.D., Chairman and CEO of MAIA, purchased 94,300 shares between November 21 and 28, 2025, at an average price of $1.08 per share. Other board members, Cristian Luput and Stan V. Smith, ...